Luke Greenwalt, MBA, on the Healthcare Executive Orders | Asembia's AXS25 Summit

In a second segment from his interview with Managed Healthcare Executive (MHE) before his talk at the 2025 Asembia meeting today..Luke Greenwalt, MBA, vice president and lead of the Market Access Center of Excellence at IQVIA, discussed what the healthcare executive orders signed by President Donald Trump on April 15 could mean for the pharmaceutical industry and market and for healthcare overall.

Many issues and changes in the orders aren't novel, noted Greenwalt, who is also a member of MHE editorial advisory board. Policy makers have been discussing PBM reform for a while, Greenwalt. One policy to watch closely is the closing of the so-called pill penalty under the Inflation Reduction Act, he said. Small-molecules are eligible for maximum fair price negotiation Under the IRA, small molecule drugs are eligible for price negotiation nine years after FDA approval and biological products after 13 years. Closing that gap would bring more investment into the development of small molecule drugs, Greenwalt said. An IQVIA analysis showed that about half of the gross and net value of drugs occurs between years 9 and 13 that they have been on the market, Greenwalt said.